CAB-B7-H3

CAB-B7-H3 is a conditionally active bispecific monoclonal antibody being developed by Himalaya Therapeutics. Designed as a T-cell engager, it simultaneously targets the B7-H3 (CD276) antigen on tumor cells and the CD3 receptor on T cells. The "CAB" (Conditionally Active Biologic) technology allows the antibody to bind preferentially to its targets within the acidic microenvironment characteristic of tumors, which is intended to minimize off-target binding and toxicity in healthy tissues. By recruiting and activating T cells in close proximity to B7-H3-expressing cancer cells, the drug facilitates direct T-cell mediated cytotoxicity. It is currently under investigation for the treatment of various solid tumors, including head and neck cancer, melanoma, lung cancers, and several other refractory malignancies.

Other names

B7-H3 x CD3 Bispecific AntibodyB-7-H3 x CD3 Bispecific AntibodyB 7-H3 x CD3 Bispecific AntibodyConditionally Active Biologic B7-H3 Bispecific